Molly Ellis ND, Medical Director Dr
Warnings Patients who have early Leber's disease (LHON) a hereditary disease that causes optic nerve atrophy have been found to suffer severe and swift optic atrophy when treated with vitamin B12
How often IV B12 is given can vary from weekly to monthly, depending on how the patient responds and the reason for the deficiency
Where they overlap and where they don't Complementary Mechanism Targets Target Origin BPC-157 Gastric juice protein fragment (15 amino acids) TB-500 Thymosin Beta-4 fragment (LKKTETQ region) Target Primary action BPC-157 Local tissue repair signaling TB-500 Systemic cell migration and mobilization Target Angiogenesis BPC-157 VEGF upregulation, NO pathway TB-500 Endothelial migration, VEGF crosstalk Target Cell migration BPC-157 Indirect, via growth factors TB-500 Direct (G-actin sequestering) Target Best-evidence tissue BPC-157 Tendon, gut, gastric mucosa (preclinical) TB-500 Cardiac, corneal, skin (preclinical + early human T4) Target Reported in vivo half-life BPC-157 ~4 hours (animal estimates) TB-500 ~23 days (animal estimates) Half-life figures are pharmacokinetic estimates from animal studies
How Vitamin Injections Compare to Oral Supplements Oral supplements can be helpful, but they must pass through the digestive system first
Always label the vial with final concentration to prevent dosing errors